1,348 Shares in Danaher Co. (NYSE:DHR) Purchased by Fairscale Capital LLC

Fairscale Capital LLC bought a new stake in Danaher Co. (NYSE:DHR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,348 shares of the conglomerate’s stock, valued at approximately $340,000.

Several other large investors have also recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new position in shares of Danaher during the second quarter valued at $67,000. Mount Yale Investment Advisors LLC grew its position in Danaher by 43.8% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 2,641 shares of the conglomerate’s stock valued at $660,000 after buying an additional 805 shares in the last quarter. Frank Rimerman Advisors LLC increased its stake in Danaher by 638.3% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 16,457 shares of the conglomerate’s stock valued at $4,112,000 after buying an additional 14,228 shares during the period. ProShare Advisors LLC raised its position in shares of Danaher by 7.9% during the 2nd quarter. ProShare Advisors LLC now owns 96,531 shares of the conglomerate’s stock worth $24,118,000 after buying an additional 7,091 shares in the last quarter. Finally, Alaethes Wealth LLC lifted its stake in shares of Danaher by 3.1% in the 2nd quarter. Alaethes Wealth LLC now owns 6,960 shares of the conglomerate’s stock worth $1,741,000 after acquiring an additional 206 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by insiders.

Danaher Stock Down 1.4 %

Danaher stock opened at $272.63 on Friday. The company has a market capitalization of $201.93 billion, a P/E ratio of 46.21, a P/E/G ratio of 4.48 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The firm’s fifty day simple moving average is $267.62 and its 200-day simple moving average is $257.16. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 earnings per share. Sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is 18.31%.

Analysts Set New Price Targets

DHR has been the subject of a number of research analyst reports. Barclays upped their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.